These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29082658)

  • 1. Cognitive impairment in progressive supranuclear palsy is associated with tau burden.
    Koga S; Parks A; Kasanuki K; Sanchez-Contreras M; Baker MC; Josephs KA; Ahlskog JE; Uitti RJ; Graff-Radford N; van Gerpen JA; Wszolek ZK; Rademakers R; Dickson DW
    Mov Disord; 2017 Dec; 32(12):1772-1779. PubMed ID: 29082658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy.
    Passamonti L; Vázquez Rodríguez P; Hong YT; Allinson KS; Williamson D; Borchert RJ; Sami S; Cope TE; Bevan-Jones WR; Jones PS; Arnold R; Surendranathan A; Mak E; Su L; Fryer TD; Aigbirhio FI; O'Brien JT; Rowe JB
    Brain; 2017 Mar; 140(3):781-791. PubMed ID: 28122879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropathological analysis of cognitive impairment in progressive supranuclear palsy.
    Sakuwa M; Adachi T; Suzuki Y; Takigawa H; Hanajima R
    J Neurol Sci; 2023 Aug; 451():120718. PubMed ID: 37385026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic influences on cognition in progressive supranuclear palsy.
    Gerstenecker A; Roberson ED; Schellenberg GD; Standaert DG; Shprecher DR; Kluger BM; Litvan I
    Mov Disord; 2017 Dec; 32(12):1764-1771. PubMed ID: 29076559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology.
    Heckman MG; Brennan RR; Labbé C; Soto AI; Koga S; DeTure MA; Murray ME; Petersen RC; Boeve BF; van Gerpen JA; Uitti RJ; Wszolek ZK; Rademakers R; Dickson DW; Ross OA
    JAMA Neurol; 2019 Jun; 76(6):710-717. PubMed ID: 30882841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Tripartite Motif Containing 11 rs564309 With Tau Pathology in Progressive Supranuclear Palsy.
    Valentino RR; Koga S; Heckman MG; Brushaber DE; Diehl NN; Walton RL; Dickson DW; Ross OA
    Mov Disord; 2020 May; 35(5):890-894. PubMed ID: 32142177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome.
    Williams DR; Holton JL; Strand C; Pittman A; de Silva R; Lees AJ; Revesz T
    Brain; 2007 Jun; 130(Pt 6):1566-76. PubMed ID: 17525140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.
    Brown RG; Lacomblez L; Landwehrmeyer BG; Bak T; Uttner I; Dubois B; Agid Y; Ludolph A; Bensimon G; Payan C; Leigh NP;
    Brain; 2010 Aug; 133(Pt 8):2382-93. PubMed ID: 20576697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Latent trait modeling of tau neuropathology in progressive supranuclear palsy.
    Kouri N; Murray ME; Reddy JS; Serie DJ; Soto-Beasley A; Allen M; Carrasquillo MM; Wang X; Castanedes MC; Baker MC; Rademakers R; Uitti RJ; Graff-Radford NR; Wszolek ZK; Schellenberg GD; Crook JE; Ertekin-Taner N; Ross OA; Dickson DW
    Acta Neuropathol; 2021 May; 141(5):667-680. PubMed ID: 33635380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive supranuclear palsy: Neuropathology of patients with a short disease duration due to unexpected death.
    Zhang L; Toyoshima Y; Takeshima A; Shimizu H; Tomita I; Onodera O; Takahashi H; Kakita A
    Neuropathology; 2021 Jun; 41(3):174-182. PubMed ID: 33205528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Whitwell JL; Lowe VJ; Tosakulwong N; Weigand SD; Senjem ML; Schwarz CG; Spychalla AJ; Petersen RC; Jack CR; Josephs KA
    Mov Disord; 2017 Jan; 32(1):124-133. PubMed ID: 27787958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional expression of the MAPT gene is associated with loss of hubs in brain networks and cognitive impairment in Parkinson disease and progressive supranuclear palsy.
    Rittman T; Rubinov M; Vértes PE; Patel AX; Ginestet CE; Ghosh BCP; Barker RA; Spillantini MG; Bullmore ET; Rowe JB
    Neurobiol Aging; 2016 Dec; 48():153-160. PubMed ID: 27697694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy.
    Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy.
    Morris HR; Schrag A; Nath U; Burn D; Quinn NP; Daniel S; Wood NW; Lees AJ
    Neurosci Lett; 2001 Oct; 312(2):118-20. PubMed ID: 11595348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atypical progressive supranuclear palsy underlying progressive apraxia of speech and nonfluent aphasia.
    Josephs KA; Boeve BF; Duffy JR; Smith GE; Knopman DS; Parisi JE; Petersen RC; Dickson DW
    Neurocase; 2005 Aug; 11(4):283-96. PubMed ID: 16093229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures.
    Valentino RR; Tamvaka N; Heckman MG; Johnson PW; Soto-Beasley AI; Walton RL; Koga S; Uitti RJ; Wszolek ZK; Dickson DW; Ross OA
    Acta Neuropathol Commun; 2020 Sep; 8(1):162. PubMed ID: 32943110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant progressive supranuclear palsy and chronic traumatic encephalopathy in a boxer.
    Ling H; Kara E; Revesz T; Lees AJ; Plant GT; Martino D; Houlden H; Hardy J; Holton JL
    Acta Neuropathol Commun; 2014 Feb; 2():24. PubMed ID: 24559032
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Schonhaut DR; McMillan CT; Spina S; Dickerson BC; Siderowf A; Devous MD; Tsai R; Winer J; Russell DS; Litvan I; Roberson ED; Seeley WW; Grinberg LT; Kramer JH; Miller BL; Pressman P; Nasrallah I; Baker SL; Gomperts SN; Johnson KA; Grossman M; Jagust WJ; Boxer AL; Rabinovici GD
    Ann Neurol; 2017 Oct; 82(4):622-634. PubMed ID: 28980714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.
    Robinson JL; Lee EB; Xie SX; Rennert L; Suh E; Bredenberg C; Caswell C; Van Deerlin VM; Yan N; Yousef A; Hurtig HI; Siderowf A; Grossman M; McMillan CT; Miller B; Duda JE; Irwin DJ; Wolk D; Elman L; McCluskey L; Chen-Plotkin A; Weintraub D; Arnold SE; Brettschneider J; Lee VM; Trojanowski JQ
    Brain; 2018 Jul; 141(7):2181-2193. PubMed ID: 29878075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of the extended tau haplotype to tau biochemistry and neuropathology in progressive supranuclear palsy.
    Liu WK; Le TV; Adamson J; Baker M; Cookson N; Hardy J; Hutton M; Yen SH; Dickson DW
    Ann Neurol; 2001 Oct; 50(4):494-502. PubMed ID: 11601500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.